Financial Performance - The company's operating revenue for 2022 was ¥958,097,728.84, a decrease of 17.34% compared to ¥1,159,145,858.49 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥163,450,635.39, down 14.78% from ¥191,797,292.57 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥123,865,236.36, reflecting a decline of 28.69% from ¥173,711,247.27 in 2021[19]. - The net cash flow from operating activities was ¥211,918,489.55, a decrease of 5.58% compared to ¥224,441,512.69 in 2021[19]. - The total assets at the end of 2022 amounted to ¥3,382,654,238.20, an increase of 130.82% from ¥1,465,507,510.72 at the end of 2021[19]. - The net assets attributable to shareholders reached ¥2,963,241,086.51, up 165.10% from ¥1,117,772,193.79 in 2021[19]. - The basic earnings per share for 2022 were ¥1.3097, a decrease of 36.08% from ¥2.0491 in 2021[19]. - The diluted earnings per share also stood at ¥1.3097, reflecting the same percentage decrease of 36.08% compared to the previous year[19]. - The weighted average return on net assets was 5.60%, down 13.06% from 18.66% in 2021[19]. - The company's total revenue for 2022 was ¥958,097,728.84, a decrease of 17.34% compared to ¥1,159,145,858.49 in 2021[62]. - Revenue from the mold and injection industry was ¥727,691,534.04, accounting for 75.95% of total revenue, down 8.69% from the previous year[63]. - Revenue from the health appliance sector dropped significantly by 38.77% to ¥212,207,856.33, which represented 22.15% of total revenue[62]. - The gross profit margin for the mold and injection industry was 35.41%, while the health appliance sector had a gross profit margin of 23.58%[63]. - In 2022, the company's total sales volume decreased by 4.90% to 598,386,628 units compared to 629,199,413 units in 2021[67]. - The production volume in the mold injection industry dropped by 12.10% to 586,748,267 units from 667,504,851 units in the previous year[67]. Cash Flow and Investments - The net cash flow from operating activities was ¥211,918,489.55, a decline of 5.58% from the previous year[75]. - Operating cash inflow decreased by 16.40% to ¥1,093,715,821.96 in 2022 compared to ¥1,308,301,513.61 in 2021[75]. - Investment cash inflow surged by 186.64% to ¥3,693,530,928.64 in 2022, compared to ¥1,288,555,907.61 in 2021[75]. - The net cash flow from financing activities increased significantly by 24,770.14% to ¥1,666,722,697.43, primarily due to new stock issuance[76]. - Cash and cash equivalents increased by 850.37% to ¥393,753,710.69 in 2022, compared to ¥41,431,728.49 in 2021[75]. - The company reported a total investment of ¥286,394,474.34 during the reporting period, a 33.98% increase compared to the previous year[85]. - The company raised a total of ¥1,999,296,000.00 through its public offering, with a net amount of ¥1,755,828,193.56 after deducting fees[93]. - The company utilized 598.19 million RMB of raised funds in 2022, with net income from bank deposits and financial products amounting to 26.68 million RMB after deducting bank fees[97]. - The company approved the use of up to 1.3 billion RMB of idle raised funds for cash management, focusing on safe and liquid financial products[101]. Research and Development - The company has invested significantly in R&D, maintaining a high level of research expenses, and has accumulated 398 authorized patents, including 20 invention patents[51]. - The company is focusing on developing a new vacuum cleaner structure to enhance product differentiation and target the mid-to-high-end market[72]. - The R&D project for the new vacuum cleaner has completed the pilot production phase, aiming for a compact design suitable for both automotive and household use[72]. - The company is working on a medical surgical minimally invasive knife product, ensuring stable production and meeting customer dimensional tolerance requirements[72]. - The development of a new slider three-stage core pulling mechanism aims to solve the issue of seamless molding for circular products, enhancing product integrity[72]. - The R&D efforts are expected to improve the company's core competitiveness and open new market directions in the medical field[72]. - The company increased its R&D personnel from 241 in 2021 to 286 in 2022, representing an 18.67% growth[74]. - R&D investment amounted to ¥58,042,510.64 in 2022, which is 6.06% of total revenue, up from 3.78% in 2021[74]. - The company has made significant advancements in R&D, including the development of high-flow conductive materials and new molding technologies[73]. Market and Product Development - The health product market, particularly air purifiers, is expected to see increased sales due to rising consumer health awareness and environmental concerns[31]. - The company has developed a "molding integration" production model, combining precision molds and injection parts, catering to diverse industries such as electronics and automotive[32]. - The overall plastic products industry is projected to maintain a steady growth trend despite global economic challenges, providing a positive environment for the company's operations[30]. - The company aims to expand its market presence through innovative product development and improved manufacturing processes[73]. - The company plans to launch two new products in Q2 2023, aiming to capture an additional 10% market share in the plastic molding industry[144]. - Future guidance estimates a revenue growth of 10-15% for 2023, driven by new product launches and market expansion efforts[144]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with a budget of 200 million RMB allocated for potential deals[144]. Corporate Governance and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements related to strategic goals and operational plans[3]. - The report highlights that all board members attended the meeting to review the annual report, ensuring accountability for its accuracy and completeness[3]. - The company maintained a complete and independent asset structure, with no disputes over ownership and no instances of asset or funds being occupied by the controlling shareholder[130]. - The company established an independent financial department with a separate accounting system, ensuring financial decision-making autonomy and compliance with regulations[131]. - The company’s governance structure has been continuously improved, ensuring independence from the controlling shareholder in operations and decision-making[126]. - The company has not engaged in any significant related party transactions that could adversely affect its independence or fairness[131]. - The company actively respects and maintains the rights of stakeholders, promoting environmental protection and corporate social responsibility[129]. - The company’s governance practices align with the regulations set forth by the China Securities Regulatory Commission, with no significant discrepancies noted[129]. - The company reported a total shareholding of 57,675,000 shares held by directors and senior management as of the end of the reporting period[135]. Employee and Social Responsibility - The total number of employees at the end of the reporting period was 1,828, with 867 in the parent company and 961 in major subsidiaries[160]. - The professional composition includes 1,183 production personnel, 80 sales personnel, 286 technical personnel, 58 financial personnel, and 221 administrative personnel[160]. - The company has established a competitive compensation system to motivate employees and promote sustainable development[161]. - A comprehensive training program is in place, including onboarding, on-the-job training, and transfer training, to enhance employee skills and career development[162]. - The company collaborates with various educational institutions to establish joint training bases and develop specialized courses[163]. - The company has fulfilled its share lock-up commitments, with the latest commitments set to expire in July 2025[187]. - The company has established a commitment to social responsibility, actively participating in charitable activities such as donations to the disabled welfare fund[181]. - The company provides a good working environment and career development opportunities for employees, adhering to labor laws and focusing on employee satisfaction[182]. Future Outlook and Strategy - The company aims to enhance customer value and create quality products and services, focusing on technology innovation and rapid response as key development strategies[109]. - Future goals include technology innovation, capacity expansion, product system optimization, market expansion, and service enhancement to ensure high-quality and steady growth[110]. - The company plans to invest in advanced manufacturing technologies, including intelligent manufacturing and micro-foaming injection molding, to shorten innovation cycles and improve R&D quality[110]. - The company will expand its production capacity in Germany, Malaysia, and Mexico to create a complementary production structure, enhancing cost and delivery advantages[111]. - The product system will be optimized to include health products, enhancing the product mix and creating new profit growth points[112]. - The company will establish overseas marketing service points in Europe, North America, and Southeast Asia to strengthen technical exchanges and improve service quality[113]. - The company faces risks from raw material price fluctuations, potential declines in gross margin, and management challenges due to rapid expansion, with strategies in place to mitigate these risks[116][117][119].

厦门唯科模塑科技股份有限公司 2023 年第一季度报告 证券代码：301196 证券简称：唯科科技 公告编号：2023-039 厦门唯科模塑科技股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 厦门唯科模塑科技股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同 期增减（%） | | --- | --- | --- | --- | | 营业收入（元） | 239,598,724.07 | 251,561,400.04 | -4.76% | | 归属于上市公司股东的净利 ...

证券代码：301196 证券简称：唯科科技 编号：2022-001 厦门唯科模塑科技股份有限公司关于召开 投资者关系活动记录表 | --- | --- | --- | |--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------| | | 特定对象调研 □ \n□ 媒体采访 □ \n□ 新闻发布会 ...

证券代码：301196 证券简称：唯科科技 编号：2022-002 厦门唯科模塑科技股份有限公司关于召开 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue for Q3 2022 was CNY 243,108,595.72, a decrease of 22.97% year-over-year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 41,696,556.20, down 27.96% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses for Q3 2022 was CNY 29,875,822.20, a decline of 45.43% year-over-year[5] - Total operating revenue for Q3 2022 was CNY 704,529,147.89, a decrease of 22.7% compared to CNY 911,660,501.79 in the same period last year[27] - Net profit for Q3 2022 was CNY 116,656,880.85, a decline of 29.0% compared to CNY 164,324,874.43 in Q3 2021[28] - Basic earnings per share for Q3 2022 were CNY 0.9310, down from CNY 1.7045 in the same quarter last year[29] - Cash received from sales of goods and services was CNY 755,839,559.50, a decrease of 17.7% from CNY 918,178,525.17 in the previous year[30] Assets and Liabilities - Total assets as of September 30, 2022, reached CNY 3,259,124,293.94, an increase of 122.39% from the end of the previous year[5] - Current assets amounted to CNY 2,332,149,824.56, compared to CNY 722,821,478.65 at the start of the year, indicating strong liquidity growth[23] - The company's total liabilities amounted to CNY 327,331,696.95, slightly down from CNY 328,713,492.67 at the end of the previous period[25] - The total liabilities decreased from CNY 1,465,507,510.72 to CNY 3,259,124,293.94, indicating a reduction in financial leverage[22] Shareholder Equity - Shareholders' equity attributable to the parent company was CNY 2,914,210,847.23, up 160.72% compared to the end of last year[5] - The total equity attributable to shareholders of the parent company reached CNY 2,914,210,847.23, significantly up from CNY 1,117,772,193.79 year-on-year[25] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 151,390,979.33, an increase of 12.39%[5] - The net cash flow from operating activities for Q3 2022 was ¥151,390,979.33, an increase of 12.5% compared to ¥134,702,059.89 in Q3 2021[31] - Total cash inflow from investment activities reached ¥2,544,538,580.35, significantly up from ¥998,146,027.26 in the same period last year[31] - The net cash flow from investment activities was -¥1,553,154,850.10, worsening from -¥92,071,570.60 year-over-year[31] - Cash inflow from financing activities amounted to ¥1,773,401,600.00, compared to only ¥619,515.44 in Q3 2021[32] - The net cash flow from financing activities was ¥1,667,867,178.21, a substantial improvement from -¥3,113,985.53 in the previous year[32] - The total cash and cash equivalents at the end of Q3 2022 stood at ¥345,735,758.75, up from ¥71,808,776.74 at the end of Q3 2021[32] Research and Development - R&D expenses for the first nine months of 2022 were CNY 43,384,855.73, a rise of 37.82% year-over-year[12] - Research and development expenses increased to CNY 43,384,855.73, up 37.9% from CNY 31,479,091.01 in the previous year[28] Inventory and Investments - Inventory decreased to CNY 235,833,325.34 from CNY 250,342,766.55, indicating improved inventory turnover[22] - The company’s long-term equity investments increased to CNY 31,731,693.51 from CNY 29,114,690.69, showing a focus on strategic investments[23] Future Outlook - The company plans to maintain its focus on expanding market presence and developing new technologies in the upcoming quarters[19]

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company's operating revenue for the reporting period was ¥461,420,552.17, a decrease of 22.59% compared to the same period last year[23]. - The net profit attributable to shareholders was ¥74,496,008.05, down 26.72% year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥59,061,691.36, reflecting a decline of 36.26% compared to the previous year[23]. - The comprehensive gross profit margin for the first half of 2022 was 32.02%, down from 33.87% in 2021[96]. - The company reported a total profit for the first half of 2022 was ¥78,747,754.39, compared to ¥71,679,196.33 in the first half of 2021, indicating a growth of 9.4%[199]. User Growth and Market Expansion - User data showed an increase in active users by 20% compared to the previous half-year, reaching 1 million active users[1]. - User data indicates a growth in active users, with the total number reaching 3 million, an increase of 15% compared to the previous year[126]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[126]. - The company is expanding its market presence in Southeast Asia, with plans to establish a new facility in Malaysia by the end of 2022[1]. Research and Development - Research and development expenses increased by 25% to 50 million RMB, focusing on innovative molding technologies[1]. - Research and development investment rose by 43.01% to ¥28,553,076.96, compared to ¥19,965,535.61 in the previous year, indicating a focus on innovation[62]. - The company has maintained a high level of R&D investment, continuously improving equipment and research conditions, and has built provincial and national-level technology centers[50]. Future Outlook - Future outlook indicates a projected revenue growth of 10% for the second half of 2022, driven by increased demand in the manufacturing sector[1]. - The company provided a positive outlook for the next quarter, projecting a revenue increase of 20% based on current market trends and user acquisition strategies[126]. - The company plans to launch two new products in Q4 2022, aiming to capture a larger market share in the automotive sector[1]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[1]. - The company reported a significant increase in cash and cash equivalents, with a net increase of 2,264.14% to ¥799,352,041.50, primarily due to new share issuance[62]. - The company plans to use up to ¥1.3 billion of idle raised funds for cash management, focusing on safe and liquid financial products[78]. - The company has a commitment to not transfer or entrust shares held prior to the IPO for 12 months from the date of listing[113]. Operational Efficiency and Risk Management - The management highlighted potential risks including supply chain disruptions and increased raw material costs, which could impact future profitability[1]. - The company is committed to continuous technological innovation and improving operational efficiency to mitigate risks associated with fluctuating raw material prices[95]. - The company is implementing new strategies to improve operational efficiency, aiming for a 15% reduction in costs over the next fiscal year[126]. Corporate Governance and Compliance - The company has implemented measures to protect investor rights, ensuring transparency and communication through various channels[109]. - The company has maintained a stable management team with no changes in directors, supervisors, or senior management during the reporting period[104]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[108]. Subsidiaries and Acquisitions - The subsidiary Shanghai Kebi experienced a significant decline in performance due to pandemic-related shutdowns and supply chain issues[91]. - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance the company's product offerings and increase market penetration by 30%[126]. - The company has expanded its business to include the production and sales of injection-molded parts and health products, establishing a "mold-integration" production model[32]. Shareholder Commitments - The company has made share lock-up commitments from January 2022 to July 2025, which are currently being fulfilled normally[112]. - The company has commitments regarding IPO price stabilization from January 2022 to January 2025, which are being fulfilled normally[113]. - The company guarantees that there will be no fraudulent issuance of shares during the IPO process[132].

厦门唯科模塑科技股份有限公司 2022 年第一季度报告全文 证券代码：301196 证券简称：唯科科技 公告编号：2022-035 厦门唯科模塑科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 251,561,400.04 | 264,095,393.20 | -4.75% | | 归属于上市公司股东的净利润（元） | 44,760,724.38 | 40, ...

Financial Performance - The company's operating revenue for 2021 was CNY 1,159,145,858.49, representing a 27.30% increase compared to CNY 910,535,393.22 in 2020[19]. - The net profit attributable to shareholders for 2021 was CNY 191,797,292.57, up 19.31% from CNY 160,756,584.19 in 2020[19]. - The net cash flow from operating activities reached CNY 224,441,512.69, an increase of 17.79% compared to CNY 190,551,383.85 in 2020[19]. - The total assets at the end of 2021 were CNY 1,465,507,510.72, reflecting an 18.91% increase from CNY 1,232,498,314.95 at the end of 2020[19]. - The basic earnings per share for 2021 was CNY 2.0491, a 19.31% increase from CNY 1.7175 in 2020[19]. - The company reported a weighted average return on equity of 18.66% for 2021, slightly down from 18.91% in 2020[19]. - The net profit after deducting non-recurring gains and losses was CNY 173,711,247.27, which is a 27.69% increase from CNY 136,040,893.94 in 2020[19]. - The company recorded quarterly revenues of CNY 264,095,393.20, CNY 331,960,010.35, CNY 315,605,098.24, and CNY 247,485,356.70 for Q1, Q2, Q3, and Q4 respectively[22]. - The company received government subsidies amounting to CNY 16,891,462.66 in 2021, compared to CNY 16,321,961.58 in 2020[25]. - The total equity attributable to shareholders at the end of 2021 was CNY 1,117,772,193.79, a 19.96% increase from CNY 931,782,994.87 at the end of 2020[19]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements related to strategic goals and operational plans[4]. - The report includes a section on potential risks the company may face in future operations, which investors are encouraged to review[4]. - The company is facing uncertainties due to the ongoing COVID-19 pandemic, which has impacted production and operations[98]. - The company will strengthen its supply chain by deepening strategic partnerships with suppliers to mitigate the impact of raw material price fluctuations[98]. Product and Market Development - The company operates in the "C29 Rubber and Plastic Products Industry," which is supported by national policies promoting high-end manufacturing and precision mold design[30]. - The precision injection mold and injection parts are widely used in electronics, automotive, and home appliance sectors, indicating a diversified market presence[31]. - The health product market, particularly air purifiers, is expected to grow significantly due to rising health awareness and the impact of the COVID-19 pandemic[32]. - The company has established a global production base with facilities in Xiamen, Shanghai, Tianjin, Quanzhou, Germany, and Malaysia, enhancing its competitive edge[31]. - The company has expanded its business model to include "mold-integration," providing a one-stop solution for clients in various industries[35]. - The company’s product line includes precision injection molds, injection parts, and health products, catering to diverse customer needs[35]. - The company is positioned to benefit from the increasing demand for lightweight materials in the automotive sector, which is expected to enhance the market for plastic molds[32]. - The company has diversified its product structure and expanded into various application markets, including electronics, automotive, home, and health appliances, effectively mitigating risks associated with market fluctuations[55]. Research and Development - Research and development investment reached CNY 43.85 million, an increase of 34.47% year-on-year, to maintain technological leadership[62]. - The number of R&D personnel increased to 241, a rise of 13.15% from 213 in 2020, with R&D personnel now accounting for 13.59% of the total workforce[76]. - The company has accumulated 370 authorized patents, including 20 invention patents, which support its long-term competitive advantage in precision injection mold design and processing[54]. - The company has invested in advanced manufacturing equipment, including five-axis CNC machining centers and automated optical inspection systems, enhancing production efficiency and quality control[55]. Corporate Governance - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[108]. - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring no shared accounts with controlling shareholders[109]. - The board of directors and senior management are elected and appointed according to legal regulations, ensuring no undue influence from shareholders[109]. - The company has a governance structure that complies with legal and regulatory requirements, with no significant discrepancies[107]. - The company has a diverse leadership team with extensive experience in the industry, enhancing its operational capabilities[113]. Environmental Responsibility - The company is committed to continuous improvement in environmental management practices[149]. - The company actively participates in social welfare, donating 60,000 yuan to the Xiamen Disabled Persons Welfare Foundation[154]. - The company has implemented measures to reduce carbon emissions, although specific details were not disclosed[156]. - The company maintains compliance with environmental standards, including wastewater and noise emissions, meeting various national regulations[156]. - The company has no significant environmental risks as it operates in a non-polluting industry[149]. Employee Management - The company emphasizes a performance-oriented compensation system to encourage employee efficiency and contributions[135]. - The company has established a comprehensive talent training mechanism, including entry training, on-the-job training, and transfer training[136]. - The total remuneration for directors, supervisors, and senior management in 2021 amounted to 3.87 million CNY[122]. - The company has a total of 1,192 production personnel, 67 sales personnel, 241 technical personnel, 59 financial personnel, and 215 administrative personnel[134]. Shareholder Returns - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares to all shareholders, based on a total of 124,800,000 shares[4]. - The cash dividend distribution will not adversely affect the company's liquidity or operational capabilities[140]. - The company has not proposed any stock bonus or capital increase through capital reserves for the year[140]. - The total distributable profit for the year is RMB 446,587,772.74[140]. Strategic Planning - The company aims to enhance customer value and create high-quality products and services, focusing on technology innovation and rapid response[94]. - The company plans to develop a modern manufacturing system integrating the entire industry chain from precision injection molds to health products[94]. - The company will continue to expand its marketing service network in Europe, North America, and Southeast Asia to better serve international clients[96]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[119].